Prognostic factors in patients with hematological malignancies and concomitant chronic hepatitis C
The study evaluated the impact of HCV infection on the prognosis in patients with hematological malignancies. A total of 96 patients with anti-HCV antibodies were enrolled, with the age of 37.8 (3.0-81.0) years old, 39.6% had non-Hodgkin's lymphoma. Chronic hepatitis C (CHC) was diagnosed in 46.9% patients prior to malignancy development, in 38.5% patients simultaneously with malignancy, and in 14.6% patients during malignancy treatment. Clinical and biochemical signs of HCH were mild in most of the patients, minimal liver fibrosis (F0-1 by METAVIR system) was discovered in 47.3% patients, severe fibrosis or cirrhosis (F3-4) was diagnosed in 40% of participants. Only 20 (20.8%) of patients received antiviral therapy against HCV prior to enrollment. Regression analysis demonstrated that age >55 years old, late onset of antiviral therapy, and poor nutritional status were significant predictors of death from hematological malignancy. Survey conducted among physicians of hematological oncology hospitals in Saint-Petersburg revealed gaps in knowledge on presentation and risks of HCV infection, as well as on opportunities of modern antiviral therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:95 |
|---|---|
| Enthalten in: |
Terapevticheskii arkhiv - 95(2023), 11 vom: 22. Dez., Seite 919-923 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
Nozhkin, M S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 03.01.2024 Date Revised 03.01.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.26442/00403660.2023.11.202473 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366495909 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366495909 | ||
| 003 | DE-627 | ||
| 005 | 20240108141333.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2023 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.26442/00403660.2023.11.202473 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1247.xml |
| 035 | |a (DE-627)NLM366495909 | ||
| 035 | |a (NLM)38158946 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 1 | |a Nozhkin, M S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prognostic factors in patients with hematological malignancies and concomitant chronic hepatitis C |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.01.2024 | ||
| 500 | |a Date Revised 03.01.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The study evaluated the impact of HCV infection on the prognosis in patients with hematological malignancies. A total of 96 patients with anti-HCV antibodies were enrolled, with the age of 37.8 (3.0-81.0) years old, 39.6% had non-Hodgkin's lymphoma. Chronic hepatitis C (CHC) was diagnosed in 46.9% patients prior to malignancy development, in 38.5% patients simultaneously with malignancy, and in 14.6% patients during malignancy treatment. Clinical and biochemical signs of HCH were mild in most of the patients, minimal liver fibrosis (F0-1 by METAVIR system) was discovered in 47.3% patients, severe fibrosis or cirrhosis (F3-4) was diagnosed in 40% of participants. Only 20 (20.8%) of patients received antiviral therapy against HCV prior to enrollment. Regression analysis demonstrated that age >55 years old, late onset of antiviral therapy, and poor nutritional status were significant predictors of death from hematological malignancy. Survey conducted among physicians of hematological oncology hospitals in Saint-Petersburg revealed gaps in knowledge on presentation and risks of HCV infection, as well as on opportunities of modern antiviral therapy | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a chronic hepatitis С | |
| 650 | 4 | |a hematologic malignancy | |
| 650 | 4 | |a hepatitis C virus | |
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a regression analysis | |
| 650 | 4 | |a surveys and questionnaires | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Lioznov, D A |e verfasserin |4 aut | |
| 700 | 1 | |a Antonova, T V |e verfasserin |4 aut | |
| 700 | 1 | |a Gorchakova, O V |e verfasserin |4 aut | |
| 700 | 1 | |a Goldstein, E M |e verfasserin |4 aut | |
| 700 | 1 | |a Popova, M O |e verfasserin |4 aut | |
| 700 | 1 | |a Shneyder, T V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Terapevticheskii arkhiv |d 1949 |g 95(2023), 11 vom: 22. Dez., Seite 919-923 |w (DE-627)NLM000055425 |x 0040-3660 |7 nnns |
| 773 | 1 | 8 | |g volume:95 |g year:2023 |g number:11 |g day:22 |g month:12 |g pages:919-923 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.26442/00403660.2023.11.202473 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 95 |j 2023 |e 11 |b 22 |c 12 |h 919-923 | ||